The effect of a paravertebral block on postoperative pain in patients with breast cancer.

The effect of a paravertebral block on postoperative pain in patients with breast cancer. - Paravertebral block and breast cancer surgery.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39535

Enrollment

100

Registered

2013-04-15

Start date

2013-12-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breastcancer

Interventions

Paravertebral block, There will be 15-20ml Ropivacaine (Ropivacaine HCl Fresenius Kabi, RVG number 104941) 0.75% given via the paravertebral catheter.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients between 18-75 year with primary breast cancer Tumor Stage 1-3, Nodes 0-2 who are scheduled for unilateral mastectomy or lumpectomy, with or without SLN and/or axillary node dissection.

Exclusion criteria

Exclusion criteria: Previous breast surgery on same breast. American Society of Anesthesiologiscts Physical Status 4 or higher Contraindication to paravertebral anesthesia and analgesia including infection of the punction area, abnormal anatomy and coagulopathy. Any contraindication to propofol, sevoflurane, fentanyl, or morphine or dipidolor.

Design outcomes

Primary

Measure	Time frame
• The pain patients will have postoperatively, will be measured by using NRS-pain rating scores.	—

Secondary

Measure	Time frame
• Nausea and vomiting, 2 hours after surgery, 1 day after surgery and 2 days after surgery. • The total consumption of analgesia postoperatively, that patients will use.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)